X0407 4 2023-06-26 1 0000891293 CTI BIOPHARMA CORP CTIC 0001339498 Craig Adam R 3101 WESTERN AVENUE, SUITE 800 SEATTLE WA 98121 1 1 0 0 President and CEO 0 Common Stock 2023-06-26 4 U 0 31470 9.10 D 0 D Stock Option (Right to Buy) 4.24 2023-06-26 4 D 0 1200000 D Common Stock 1200000 0 D Stock Option (Right to Buy) 3.19 2023-06-26 4 D 0 450000 D Common Stock 450000 0 D Stock Option (Right to Buy) 4.14 2023-06-26 4 D 0 475000 D Common Stock 475000 0 D Stock Option (Right to Buy) 1.88 2023-06-26 4 D 0 600000 D Common Stock 600000 0 D Stock Option (Right to Buy) 0.8411 2023-06-26 4 D 0 470054 D Common Stock 470054 0 D Stock Option (Right to Buy) 1.00 2023-06-26 4 D 0 2320000 D Common Stock 2320000 0 D Stock Option (Right to Buy) 3.30 2023-06-26 4 D 0 800000 D Common Stock 800000 0 D Stock Option (Right to Buy) 4.49 2023-06-26 4 D 0 1115000 D Common Stock 1115000 0 D Stock Option (Right to Buy) 4.55 2023-06-26 4 D 0 900000 D Common Stock 900000 0 D Includes 2,030 shares of common stock of the Issuer ("Company Common Stock") purchased by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan prior to the date of this Form 4. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of Company Common Stock and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $9.10 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. /s/ Adam R. Craig 2023-06-26